Spruce Biosciences, Inc. Common Stock
$53.05
-$0.81 (-1.50%)
$51.80Day Range$53.86
Key Statistics
Market Cap
$154.79M
Shares Outstanding
2.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 9, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$53.04
Day High
$53.86
Day Low
$51.80
Volume
99.6K
VWAP
$52.86
Prev Close
$53.86
Transactions
--
Acc. Volume
--
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
PHARMACEUTICAL PREPARATIONSSIC 28348 employees611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO, CA, 94080(415) 655-4168IPO Oct 9, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001683553
- Composite FIGI
- BBG00HYZ1522
- Share Class FIGI
- BBG00HYZ1559
- Ticker Root
- SPRB
- SIC Code
- 2834
About Spruce Biosciences, Inc. Common Stock (SPRB) Stock
Spruce Biosciences, Inc. Common Stock (SPRB) closed the 2026-09-18 session at $53.05, down 1.50% versus the previous close (-0.81). The stock opened at $53.04 and traded between $51.80 and $53.86 during that session. Session trading volume was 100K shares. The volume-weighted average price (VWAP) is $52.86.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Spruce Biosciences, Inc. Common Stock has a market capitalization of $154.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SPRB is listed on the XNAS exchange. The company employs approximately 8 people. Spruce Biosciences, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2020-10-09.
On this page you can find market SPRB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.